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Background. Many studies have examined the efﬁcacy of psychotherapy for major depressive disorder (MDD) but
publication bias against null results may exist in this literature. However, to date, the presence of an excess of signiﬁcant
ﬁndings in this literature has not been explicitly tested.
Method. We used a database of 1344 articles on the psychological treatment of depression, identiﬁed through systematic
search in PubMed, PsycINFO, EMBASE and the Cochrane database of randomized trials. From these we identiﬁed
149 studies eligible for inclusion that provided 212 comparisons. We tested for an excess of signiﬁcant ﬁndings using
the method developed by Ioannidis and Trikalinos (2007), and compared the distribution of p values in this literature
with the distribution in the antidepressant literature, where publication bias is known to be operating.
Results. The average statistical power to detect the effect size indicated by the meta-analysis was 49%. A total of
123 comparisons (58%) reported a statistically signiﬁcant difference between treatment and control groups, but on the
basis of the average power observed, we would only have expected 104 (i.e. 49%) to do so. There was therefore evidence
of an excess of signiﬁcance in this literature (p=0.010). Similar results were obtained when these analyses were restricted
to studies including a cognitive behavioural therapy (CBT) arm. Finally, the distribution of p values for psychotherapy
studies resembled that for published antidepressant studies, where publication bias against null results has already been
established.
Conclusions. The small average size of individual psychotherapy studies is only sufﬁcient to detect large effects.
Our results indicate an excess of signiﬁcant ﬁndings relative to what would be expected, given the average statistical
power of studies of psychotherapy for major depression.
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Introduction
Many studies have examined the efﬁcacy of psy-
chotherapy for major depressive disorder (MDD),
and have established that psychotherapy is effective
in the treatment of psychiatry’s commonest illness
(Elkin et al. 1989). Meta-analyses of these primary
studies indicate that the effect of psychotherapies on
MDD is comparable to those of antidepressant medica-
tions (Cuijpers et al. 2008b). However, there seems to
be publication bias against null results for studies of
both psychotherapies (Cuijpers et al. 2010, 2011) and
antidepressant medications (Kirsch et al. 2008; Turner
et al. 2008).
The existence of unpublished null ﬁndings
means that the published literature contains an over-
representation of positive ﬁndings and, as a result,
corresponding estimates of effect size are likely to be
inﬂated, overstating the efﬁcacy of the intervention.
Several factors may contribute to publication bias,
including the reluctance of journals to publish null
results and the lack of incentives for authors to invest
time in writing up these studies (which are generally
regarded as ‘less interesting’). In the case of studies
of antidepressant medication, publication bias is also
often attributed, at least in part, to the motivation of
the pharmaceutical industry to suppress unfavour-
able results for commercial reasons. However, this
motivation would not seem to apply to studies of
psychotherapy.
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There is growing evidence for the existence of publi-
cation bias in the psychotherapy literature, similar
to that observed in the antidepressant literature. For
example, Cuijpers et al. (2010) estimated from 89
studies of the efﬁcacy of cognitive behavioural therapy
(CBT) that the equivalent of 26 null studies remained
unpublished, and statistically adjusting for this publi-
cation bias reduced the pooled effect size considerably.
This adjustment is likely to be conservative because it
depends on an analysis of a funnel plot, in which the
study size (i.e. precision) is compared to the reported
effect size. The idea underlying a funnel plot is that
smaller studies are more likely to be published if
they have larger than average effect sizes, resulting
in an asymmetrical distribution around the pooled
effect size. However, this method is relatively insensi-
tive, particularly when there is a narrow range of
sample sizes within the studies contributing to the
meta-analysis (Lau et al. 2006). Funnel plots may there-
fore not be an effective diagnostic method for assessing
the psychotherapy literature, where studies tend to be
similar in size.
Tests of small-study effects are used to evaluate
whether effect sizes are related to study size (e.g.
funnel plot methods). An alternative approach is to
test for an excess of statistically signiﬁcant ﬁndings,
which more directly evaluates whether the number of
statistically signiﬁcant results in a corpus of studies
is higher than would be expected given a plausible
estimate of the likely true effect size. This method, de-
veloped by Ioannidis & Trikalinos (2007), has been
used previously to investigate ‘excess of signiﬁcance’
in speciﬁc literatures (Ioannidis, 2011; Button et al.
2013a,b; Murphy et al. 2013). It typically uses meta-
analysis of the literature to arrive at an estimate of
the likely true population effect size and then, given
the power of each individual study to detect an effect
of that magnitude, compares the expected with the
observed (i.e. published) number of signiﬁcant
ﬁndings.
We therefore set out to apply this test to studies
of psychotherapy for depression, using an updated
database of studies that has been used in a series of
previous meta-analyses (Cuijpers et al. 2008b, 2011).
Method
Identiﬁcation and selection of studies
We used a database of 1344 articles on the psycholo-
gical treatment of depression that has been described
in detail elsewhere (Cuijpers et al. 2008b, 2011), and
that has been used in a series of earlier published
meta-analyses (www.evidencebasedpsychotherapies.
org). This database is continuously updated through
comprehensive literature searches (currently from
1966 to January 2012). We examined 13407 abstracts
identiﬁed from PubMed (3320 abstracts), PsycINFO
(2710), EMBASE (4389) and the Cochrane Central
Register of Controlled Trials (2988). These abstracts
were identiﬁed by combining terms indicative of
psychological treatment and depression (both MeSH
terms and text words). We also searched the primary
studies from 42 meta-analyses of psychological treat-
ment for depression to ensure that no published stud-
ies were missed. From the 13407 abstracts, we
identiﬁed 9860 unique abstracts after the removal of
duplicates. Of these, 8516 were excluded based on
the title and abstract, so that 1344 full-text articles
were retrieved for possible inclusion in the database.
Of these, 1164 articles were excluded (Fig. 1), resulting
in the inclusion of 180 articles in the database.
For the present meta-analysis, included studies were
randomized controlled trials in which a psychological
intervention was compared to a control condition
(waiting list; usual care; placebo; other) in people
with depression (deﬁned as an MDD according to a di-
agnostic interview, or as scoring above a cut-off on a
self-report instrument). Excluded studies were studies
of in-patients and adolescents (<18 years), and studies
in which the effect size could not be calculated ex-
actly (typically because only an overall p value was
given for the comparison between treatment and con-
trol group at post-test, and no other information
could be used to calculate the effect size). Co-morbid
general medical or psychiatric disorders were not
an exclusion criterion, and no language restriction
was applied.
Quality assessment
We assessed the validity of included studies using four
criteria of the ‘risk of bias’ assessment tool, developed
by the Cochrane Collaboration (Higgins & Green,
2011). This tool assesses possible sources of bias in ran-
domized trials, including: the adequate generation of
allocation sequence; the concealment of allocation to
conditions; the prevention of knowledge of the allo-
cated intervention (masking of assessors); and dealing
with incomplete outcome data [this was assessed as
positive when intent-to-treat (ITT) analyses were con-
ducted, meaning that all randomized patients were in-
cluded in the analyses]. The assessment tool includes
two other criteria: evidence of selective outcome
reporting; and other problems that could put it at a
high risk of bias. The latter two criteria were not
used in the present research because we found no indi-
cation in any of the studies that these had inﬂuenced
the validity of the study.
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Statistical analysis
We ﬁrst calculated individual study effect sizes, reﬂect-
ing the difference between the psychotherapy group
and the control group at post-test (Hedges’ g or stan-
dardized mean difference). Effect sizes were calculated
by subtracting (at post-test) the average score of
the psychotherapy group from the average score of
the control group, and dividing the result by the
pooled standard deviations of the two groups. As
several studies had relatively small sample sizes, we
corrected the effect size for small sample bias accord-
ing to the procedure suggested by Hedges & Olkin
(1985), which corrects the pooled standard deviation
to provide a more unbiased estimate of the population
effect size. When calculating effect sizes, we only used
those instruments that explicitly measured symptoms
of depression, such as the Beck Depression Inventory
(BDI) or the Hamilton Depression Rating Scale
(HAMD). If more than one depression measure
was used, the mean of the effect sizes was cal-
culated, so that each comparison yielded only
one effect size. If means and standard deviations
were not reported, we calculated the effect size using
dichotomous outcomes or other statistics that were
available for calculating effect sizes (e.g. t statistic or
p value).
We next calculated the summary effect size within
both ﬁxed and random effects frameworks. To estimate
the heterogeneity of individual study effect sizes, we
calculated the I2 statistic. A value of 0% indicates no
observed heterogeneity, with larger values indicating
increasing heterogeneity. Conventionally, 25% is
regarded as low, 50% as moderate and 75% as high
heterogeneity (Higgins et al. 2003). We also calculated
the Q statistic. We explored the impact of study-level
characteristics by stratifying our analysis by: analysis
(ITT, per protocol); independent randomization
(yes, no); control group (usual care, wait list, other);
blinding of assessors (yes, no, not known); and country
Fig. 1. Flowchart of inclusion of studies.
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(UK, EU, USA, Australia, Canada, Other). We also con-
ducted a meta-regression of effect size estimate on
number of treatment sessions. Analyses were con-
ducted using Comprehensive Meta-Analysis version
2.2.021 (Biostat, USA).
Finally, we calculated the achieved power for each
study to detect the estimated summary effect reported
in the meta-analysis, assuming an α level of 5%.
Power was calculated using G*Power software
(Faul et al. 2007). We then calculated the mean and
median statistical power across all studies. The num-
ber of expected studies with statistically signiﬁcant
results was estimated, based on the average statistical
power of individual studies given the likely true effect
size, and compared against the number of observed
signiﬁcant studies to test for an excess of statistically
signiﬁcant results (Ioannidis & Trikalinos, 2007).
This approach is conservative because it is based
upon observed signiﬁcant ﬁndings from those indi-
vidual study effects in our meta-analysis. These effect
sizes do not include adjustment for covariates as may
have been the case in the published reports of those
data.
Results
Description of studies
From the 180 articles included in the database, 149
were eligible for inclusion in our analysis. Of these,
49 included more than one active treatment arm, so
that there were a total of 212 comparisons between
psychotherapy and control conditions. The character-
istics of the included studies are shown in the online
Supplementary Table S1.
Meta-analysis
Meta-analysis of the 149 psychotherapy studies iden-
tiﬁed by our search strategy indicated a summary
effect size of d=0.55 (95% CI 0.52–0.58, p<0.001) within
a ﬁxed effects framework and d=0.65 (95% CI 0.57–0.72,
p<0.001) within a random effects framework. There
was evidence of substantial heterogeneity (I2=72%,
Q148=625, p<0.001).
The 92 studies that included a CBT arm indicated
a summary effect size of d=0.58 (95% CI 0.54–0.63,
p<0.001) within a ﬁxed effects framework and d=0.71
(95% CI 0.61–0.80, p<0.001) within a random effects
framework. There was again evidence of substantial
heterogeneity (I2=79%, Q91=429, p<0.001).
Stratiﬁcation by study-level characteristics indicated
that the summary effect size estimate was larger when
analysis was per protocol rather than ITT, when there
was no independent randomization, and when a wait
list control was used. Meta-regression indicated a
weak positive association between effect size and num-
ber of treatment sessions (slope 0.009, 95% CI 0.001–
0.018, p=0.032). These results are summarized in
Table 1.
Excess signiﬁcance in all psychotherapy studies
For all 212 psychotherapy comparisons, the mean sam-
ple size was 35 (median 22) in the treatment group and
34 (median 21) in the control group. Assuming the
summary effect size for all psychotherapy studies
(d=0.55) indicated by our meta-analysis represents a
reasonable estimate of the true population effect size,
we calculated the power of each comparison to detect
such an effect. This indicated that the average stati-
stical power was 49%. A total of 123 comparisons
(58%) reported a statistically signiﬁcant (i.e. p<0.05)
difference between treatment and control groups,
However, on the basis of the average power observed,
we would only expect 104 (i.e. 49%) to do so. There
was therefore evidence of an excess of signiﬁcance in
this literature (p=0.010). These results did not change
substantively when the 149 individual studies (rather
than comparisons) were considered (observed: 96,
expected: 84, p=0.051).
Excess signiﬁcance in CBT studies
We next restricted our analysis to the 139 comparisons
that included a CBT arm. The mean sample size was 36
(median 23) in the treatment group and 36 (median 23)
in the control group. The summary effect size for
all CBT studies (d=0.58) indicated that the average
statistical power was 53%. A total of 87 comparisons
(63%) reported a statistically signiﬁcant difference be-
tween treatment and control groups whereas we
would expect only 73 (i.e. 53%) to do so. Therefore,
again, there was evidence of an excess of signiﬁcance
in this literature (p=0.028). These results did not
change substantively when the 92 individual studies
(rather than comparisons) were considered (observed:
65, expected: 54, p=0.006).
p-value distributions for antidepressant and
psychotherapy studies
We know empirically that publication bias operates
in the antidepressant literature (i.e. some studies
remained unpublished), from data obtained from the
US Food and Drug Administration (Kirsch et al.
2008). It is therefore of interest to directly compare
the antidepressant and psychotherapy literatures.
One way of doing this is to compare the distribution
of p values in both literatures. We used data from
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published and unpublished clinical trials of four anti-
depressants (Kirsch et al. 2008; Horder et al. 2011)
to compare the distribution of p values for all studies,
and for published studies only, within speciﬁc ranges
(<0.01, 0.01–0.05, 0.05–0.10, >0.10).
The entire antidepressant literature contains several
studies where p>0.10, but this proportion is lower
among published antidepressant studies, with a corre-
sponding increase in the proportion of studies where
p<0.01. This is consistent with what we would expect
to see if publication bias against null results is operat-
ing. We also plotted the distribution of p values for
all psychotherapy studies, and only those studies that
included a CBT arm. In both cases, the observed distri-
butions resemble the published (i.e. biased) rather than
total (i.e. published and unpublished) literature on
antidepressant studies. These results are shown in
Fig. 2.
Discussion
Our analysis of studies of the effectiveness of psy-
chotherapy for MDD indicates that there is an excess
of signiﬁcant ﬁndings relative to what would be
expected given the average statistical power of these
studies. These results were not altered when we restric-
ted our analysis to studies of CBT. The distribution of
p values in this literature also resembles that of the
published antidepressant literature, where publication
bias against null results has already been established.
We also noted the small average size of individual
psychotherapy studies, which would only be sufﬁcient
to detect relatively large effects. An excess of signiﬁ-
cance in a speciﬁc literature may be due to several fac-
tors, including null results remaining unpublished and
null results that are presented as positive. The preva-
lence of unpublished null ﬁndings has previously
Table 1. Meta-analysis stratiﬁed by study-level characteristics
k g 95% CI p value I2 (%) pdiff
All studies
Fixed effects 149 0.55 0.52–0.59 <0.001 76 N.A.
Random effects 0.65 0.57–0.72 <0.001
CBT studies
Fixed effects 92 0.58 0.54–0.63 <0.001 79 N.A.
Random effects 0.71 0.61–0.80 <0.001
Analysis
ITT 82 0.54 0.46–0.62 <0.001 71 0.002
Per protocol 67 0.80 0.65–0.96 <0.001 79
Randomizationa
Yes 62 0.49 0.41–0.58 <0.001 70 <0.001
No 87 0.79 0.66–0.91 <0.001 77
Control group
Other 28 0.40 0.26–0.53 <0.001 68 <0.001
Usual care 61 0.55 0.45–0.66 <0.001 71
Wait list 60 0.87 0.75–1.01 <0.001 77
Blindingb
Yes 122 0.61 0.54–0.68 <0.001 69 0.26
No 15 0.82 0.52–1.12 <0.001 72
Not known 12 0.83 0.40–1.26 <0.001 93
Country
UK 22 0.43 0.31–0.55 <0.001 42 0.004
EU 24 0.53 0.41–0.66 <0.001 59
USA 75 0.64 0.53–0.74 <0.001 71
Australia 9 0.65 0.30–1.00 <0.001 79
Canada 5 0.87 0.24–1.50 0.007 81
Other 14 1.10 0.76–1.45 <0.001 92
CBT, Cognitive behavioural therapy; ITT, intent to treat; CI, conﬁdence interval; N.A., not applicable.
Stratiﬁed analyses were conducted within a random effects framework.
a Independent randomization.
b Blinding of assessors.
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been reported through meta-analysis of the psycho-
therapy literature (Cuijpers et al. 2010). Moreover, the
misrepresentation of null ﬁndings has been docu-
mented in trials of antidepressant drugs (Turner et al.
2008). The latter bias seems to be operating also in
the ﬁeld of psychotherapy treatment, despite an appar-
ent lack of overt ﬁnancial incentives to do so. This is
perhaps not surprising, given growing evidence that
similar patterns are present across a diverse range of
literatures and methodologies (Button et al. 2013a,b).
There are some limitations to our study to be con-
sidered. First, our meta-analysis indicated substantial
between-study heterogeneity, making the choice of
an appropriate effect size for the excess of signiﬁcance
test difﬁcult. Simulations suggest that the most appro-
priate effect size to use when testing for excess signiﬁ-
cance is that derived from a ﬁxed effects meta-analysis,
or the effect size of the largest study included in each
meta-analysis (Ioannidis, 2013). This is because effect
sizes from random effects meta-analysis are typically
larger than those from ﬁxed effects meta-analysis
(albeit with wider CIs), and they are particularly
prone to inﬂation in the presence of reporting biases
that predominantly affect smaller studies (Ioannidis,
2013).
Second, we did not include adjustment for covariates
when calculating individual study effect sizes.
However, given that all studies were randomized, we
do not view this as a major limitation. Rather, our ap-
proach ensures that all data are treated in the same
way, removing the scope for ‘researcher degrees of
freedom’ (Simmons et al. 2011) inﬂuencing the effect
size estimate for individual studies.
Third, we combined all psychotherapy approaches,
and only conducted separate analyses for CBT. This
was in part a pragmatic decision, given the large num-
ber of psychotherapy approaches. However, there
seem to be few differences between the effects of differ-
ent types of psychotherapies for depression (Cuijpers
et al. 2008a; Barth et al. 2013). Nevertheless, it may be
that the problem of excess signiﬁcance is more pro-
nounced for some literatures than others.
Fourth, our ﬁndings depend on the choice of a
plausible effect size: the larger the effect, the larger
the power of each study to detect that effect. The esti-
mates from the meta-analysis are likely to be upwardly
biased (for example, because of publication bias).
Therefore, we suggest that our estimate of the excess
of signiﬁcance in this literature is likely to be conserva-
tive because, were the true effect size in fact less than
the average published effect size, the average power
of the studies to detect this effect would be even
smaller.
Fifth, the true population effect size may vary sys-
tematically with sample size; for example, if there are
cultural differences in the efﬁcacy of psychotherapy
for depression, the population effect size may vary
across countries. If scientists within those countries
are aware of this, they may calculate their sample
sizes accordingly. Other methods have been developed
to test for excess of signiﬁcance, such as calculating the
post-hoc power for individual studies, which could ac-
commodate this. However, this method has typically
been used when an effect size estimate from a
meta-analysis is not available (Francis, 2012). Given
that there are no strong reasons to believe that the
Fig. 2. Proportion of published psychotherapy studies, and published and unpublished antidepressant studies, reporting
p values within a speciﬁc range. The proportion of studies reporting p values within a speciﬁc range are shown for all
antidepressant studies (k=35), published antidepressant studies only (k=23), published psychotherapy comparisons (k=212),
and published psychotherapy comparisons that included a cognitive behavioural (CBT) therapy arm (k=139). In both the
latter cases, the observed distributions resemble the distribution of published antidepressant studies only, where we know
publication bias is operating.
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true population effect size varies systematically with
sample size, and that an effect size estimate derived
from a meta-analysis is available, we consider our
approach is most appropriate.
In conclusion, there exists an excess of signiﬁcance
in the literature on psychotherapy for depression.
Although similar observations have been made of the
antidepressant literature, it is instructive to see that
an excess of signiﬁcance can occur in a literature
where ﬁnancial vested interests are less likely to play
a part. Our results have potentially important implica-
tions; in particular, the excess of signiﬁcance we have
observed in this literature, together with previous evi-
dence of publication bias, emphasizes the importance
of publishing null trial results. The AllTrials campaign
(www.alltrials.net/) calls for all past and present clini-
cal trials to be registered and their results reported,
so that the efﬁcacy and effectiveness of treatments
can be properly assessed. If null results remain unpub-
lished, then it follows that psychotherapy for depre-
ssion (in this case) may be less effective than the
published literature would suggest. There is interest
in providing psychotherapy on a large scale in the
UK (Clark, 2011) and elsewhere, which would require
substantial ﬁnancial investment. Consequently, it
would be prudent to rigorously establish the effective-
ness of the therapies that might be so provided, and
the likely magnitude of their effect.
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